The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

About one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them resistant to endocrine therapy and able to grow uncontrolled. A team of researchers ...

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, ...

Researchers are beginning to understand the benefit of resistance exercise in the management of anxiety and depression. The effects of resistance training on the management of anxiety and depression ...

The concept of therapy resistance was initially introduced by the pioneering psychoanalyst Sigmund Freud. Freud described it as an unconscious unwillingness to bring the unknown into the light and to ...